Skip to main content
Division of Rheumatology, Autoimmunity and Inflammation RAI

 Clinical Trials

  1. Division of Rheumatology, Autoimmunity & Inflammation
  2. Research
  3. Center for Innovative Therapy (CIT)
  4. Clinical Trials

Current Clinical Studies

If you are interested in finding out more information about a particular study, please contact the study personnel, Ms. Linda Mendoza at (858) 246-2389.

Systemic Lupus Erythematosus (SLE)

Interventional Abbvie SELECT-SLE: A Phase 3 Program to Evaluate the Safety and Efficacy of Upadacitinib in Subjects with Moderately to Severely Active Systemic Lupus Erythematosus Kenneth Kalunian, M.D.
Study Type Sponsor Details Principal Investigator
Interventional Artiva A Phase 1 Study to Evaluate the Efficacy and Safety Of AB-101, an Allogeneic Cord Blood Derived NK-Cell Therapy in Combination With B-Cell Depleting monoclonal, in Patients Who Failed Treatment for Refractory Systemic Lupus Erythematosus Bethany Karl, D.O.
Interventional Biogen TOPAZ-1: A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of BIIB059 in Adult Participants With Active Systemic Lupus Erythematosus Receiving Background Nonbiologic Lupus Standard of Care Arthur Kavanaugh, M.D.
Interventional BMS A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Study to Evaluate the Efficacy and Safety of Afimetoran in Participants with Active Systemic Lupus Erythematosus Chelsey Smith, M.D.
Interventional BMS POETYK SLE-2: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Deucravacitinib in Participants with Active Systemic Lupus Erythematosus Chelsey Smith, M.D.
Interventional CuGENE A Phase Ib, Randomized, Double-Blind, Placebo-Controlled, Ascending-Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Subcutaneously Administered CUG252 following Multiple Dose Administrations in Participants with Mild-to-Moderate Systemic Lupus Erythematosus Kenneth Kalunian, M.D.
Interventional Feinstein Pilot Trial of Belimumab in Early Lupus Kenneth Kalunian, M.D.
Interventional Galapagos GALARISSO: A Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Orally Administered GLPG3667 in Adult Subjects with Active Systemic Lupus Erythematosus Kenneth Kalunian, M.D.
Interventional Idorsia OPUZ-2: A Phase 3, Multicenter, Randomized, Double-blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy, Safety, and Tolerability of Cenerimod in Adult Subjects with Moderate-to-Severe Systemic Lupus Erythematosus on Top of Background Therapy Kenneth Kalunian, M.D.
Interventional Novartis SIRIUS-SLE 1: A Randomized, Double-Blind, Parallel Group, Placebo-Controlled Multicenter Phase 3 Study to Evaluate Efficacy, Safety and Tolerability of Two Regimens of Ianalumab on Top of Standard-of-Care Therapy in Patients with Systemic Lupus Erythematosus Chelsey Smith, M.D.

Cutaneous Lupus Erythematosus (CLE)

Interventional Gilead COSMIC: A Randomized, Blinded, Placebo-Controlled, Phase 2a, Proof-of-Concept Study to Evaluate Efficacy, Safety, and Tolerability of GS-5718 in Participants With Cutaneous Lupus Erythematosus Arthur Kavanaugh, M.D.
Study Type Sponsor Details Principal Investigator
Interventional Astra Zeneca LAVENDER: A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase III Study to Evaluate the Efficacy and Safety of Anifrolumab in Adults with Chronic and/or Subacute Cutaneous Lupus Erythematosus who are Refractory and/or Intolerant to Antimalarial Therapy Arthur Kavanaugh, M.D.
Interventional Biogen AMETHYST: A 2-Part Seamless Part A (Phase 2)/Part B (Phase 3) Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of BIIB059 in Participants With Active Subacute Cutaneous Lupus Erythematosus and/or Chronic Cutaneous Lupus Erythematosus With or Without Systemic Manifestations and Refractory and/or Intolerant to Antimalarial Therapy Arthur Kavanaugh, M.D.

Systemic Sclerosis (SSc)

Study Type Sponsor Details Principal Investigator
Interventional Atyr EFZO-CONNECT: Randomized, Double-Blind, Placebo-Controlled Proof of Concept Study to Evaluate the Efficacy, Safety and Tolerability of Efzofitimod in Patients with Systematic Sclerosis Related Interstitial Lung Disease Arthur Kavanaugh, M.D.

Lupus Nephritis (LN)

Study Type Sponsor Details Principal Investigator
Interventional Artiva A Phase 1 Study to Evaluate the Efficacy and Safety Of AB-101, an Allogeneic Cord Blood Derived NK-Cell Therapy in Combination With B-Cell Depleting monoclonal, in Patients Who Failed Treatment for Class III or IV Lupus Nephritis Bethany Karl, D.O.
Interventional HI-Bio An Open Label Phase 1b Study of Felzartamab in Lupus Nephritis Kenneth Kalunian, M.D.

Sjogren

Interventional Horizon OASIZ-303: A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Dazodalibep in Participants With Sjögren’s Syndrome With Moderate-to-Severe Symptom State Monica Guma, M.D., Ph.D.
Study Type Sponsor Details Principal Investigator
Interventional Horizon OASIZ-301: A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Dazodalibep in Participants With Sjögren’s Syndrome With Moderate-to-severe Systemic Disease Activity Monica Guma, M.D., Ph.D.